Recurrent glomerular disease after kidney transplantation

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 6, 2010, Pages 578-585

  Fairhead, Todd ^a,c,d   Knoll, Greg ^a,b,c,d  

^a Kidney Research Centre   (Canada)

^b Clinical Epidemiology Program   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

glomerulonephritis; immunosuppression; kidney transplantation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

ALPORT SYNDROME; ANCA ASSOCIATED GLOMERULONEPHRITIS; CHRONIC GRAFT REJECTION; DRUG EFFICACY; DRUG MEGADOSE; FOCAL GLOMERULONEPHRITIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

GLOMERULONEPHRITIS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RECURRENCE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78049240316     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833d6904     Document Type: Review

References (88)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4:1289-1295.
2. Matas AJ. Recurrent disease after kidney transplantation: it is time to unite to address this problem! Am J Transplant 2006; 6:2527-2528.
3. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103-109.
4. Knoll G, Muirhead N,Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5:1719-1724.
5. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535-2542.
6. Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol 2008; 4:446-457.
7. - 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1998-2007. In: U.S., Department of Health, Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation, editor. Rockville, MD. 2008.
8. Hariharan S, Peddi VR, Savin VJ, et al. Recurrent and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry. Am J Kidney Dis 1998; 31:928-931.
9. Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635-641.
10. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527-535.
11. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical char-acterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant 2010; 10:324-330.
12. Mulay AV, van Walraven C, Knoll GA. Impact of immunosuppressive medica-tion on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 2009; 9:804-811.
13. DonadioJV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738-748.
14. Hiki Y. O-linked oligosaccharides of the IgA1 hinge region: roles of its aberrant structure in the occurrence and/or progression of IgA nephropathy. Clin Exp Nephrol 2009; 13:415-423.
15. Berger J, Noel LH, Nabarra B. Recurrence of mesangial IgA nephropathy after renal transplantation. Contrib Nephrol 1984; 40:195-197.
16. Odum J, Peh CA, Clarkson AR, et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 1994; 9:309-312.
17. Wang AY, Lai FM, Yu AW, et al. Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 2001; 38:588-596.
18. PonticelliC, Traversi L, Feliciani A, et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001; 60:1948-1954.
19. Andresdottir MB, HoitsmaAJ, Assmann KJ, WetzelsJF. Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol 2001; 56:279-288.
20. Choy BY, Chan TM, Lo SK, et al. Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant 2003; 18:2399-2404.
21. MoriyamaT, Nitta K, Suzuki K, et al. Latent IgA deposition from donor kidney is the major riskfactorfor recurrent IgA nephropathy in renal transplantation. Clin Transplant 2005; 19 (Suppl 14):41-48.
22. Ng YS, Vathsala A, Chew ST, et al. Long term outcome of renal allografts in patients with immunoglobulin A nephropathy. Med J Malaysia 2007; 62:109-113.
23. Mousson C, Charon-Barra C, Funes de la Vega M, et al. Recurrence of IgA nephropathy with crescents in kidney transplants. Transplant Proc 2007; 39:2595-2596.
24. Tang Z, Ji SM, Chen DR, et al. Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation. Ren Fail 2008; 30:611-616.
25. Berthoux F, El DeebS, MariatC, et al. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 2008; 85:1505-1507.
26. Courtney AE, McNamee PT, Nelson WE, Maxwell AP. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 2006; 21:3550-3554.
27. Kennoki T, Ishida H, Yamaguchi Y, Tanabe K. Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation. Transplantation 2009; 88:935-941.
28. Ushigome H, Suzuki T, Fujiki M, et al. Efficacy of tonsillectomy for patients with recurrence of IgA nephropathy after kidney transplantation. Clin Transplant 2009; 23 (Suppl 20):17-22.
29. TsuchiyaT, ItoS, Yamaguchi Y, et al. Tonsillectomy and steroid pulse therapy for recurrent IgA nephropathy in renal allograft. Clin Nephrol 2010; 73:68-71.
30. Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 2010; 25:25-31.
31. Newstead CG. Recurrent disease in renal transplants. Nephrol Dial Transplant 2003; 18 (Suppl 6):vi68-74.
32. Stokes MB, De Palma J. Posttransplantation nephrotic syndrome. Kidney Int 2006; 69:1088-1091.
33. Weber S, Tonshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 2005; 80 (1 Suppl):S128-S134.
34. Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232-1239.
35. Sener A, Bella AJ, Nguan C, et al. Focal segmental glomerular sclerosis in renal transplant recipients: predicting early disease recurrence may prolong allograft function. Clin Transplant 2009; 23:96-100.
36. Ehrich JH, Rizzoni G, Brunner FP, et al. Combined report on regular dialysis and transplantation of children in Europe, 1989. Nephrol Dial Transplant 1991; 6 (Suppl 1):37-47.
37. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334:878-883.
38. Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5:2907-2912.
39. Matalon A, Markowitz GS, Joseph RE, et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001; 56:271-278.
40. Raafat RH, Kalia A, Travis LB, Diven SC. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 2004; 44:50-56.
41. Montagnino G, Tarantino A, Banfi G, et al. Double recurrence of FSGS after two renal transplants with complete regression after plasmapheresis and ACE inhibitors. Transpl Int 2000; 13:166-168.
42. Requiao-Moura LR, Moscoso-Solorzano GT, Franco MF, et al. Prognostic factors associated with poor graft outcomes in renal recipients with post-transplant glomerulonephritis. Clin Transplant 2007; 21:363-370.
43. Dello Strologo L, Guzzo I, Laurenzi C, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009; 88:417-420.
44. El-Firjani A, Hoar S, Karpinski J, et al. Posttransplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 2008; 23:425.
45. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008; 8:222-227.
46. Rodriguez-Ferrero M, Ampuero J, Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 2009; 41:2406-2408.
47. Leroy S, Guigonis V, Bruckner D, et al. Successful anti-TNFalphatreatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant 2009; 9:858-861.
48. Savin VJ, McCarthy ET, Sharma R, et al. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 2008; 151:288-292.
49. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11-21.
50. El-Zoghby ZM, Grande JP, Fraile MG, et al. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009; 9:2800-2807.
51. Dabade TS, Grande JP, Norby SM, et al. Recurrent idiopathic membranousnephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant 2008; 8:1 318-1322.
52. Sprangers B, Lefkowitz GI, Cohen SD, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 2010; 5:790-797.
53. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14:1851-1857.
54. Gallon L, Chhabra D. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 2006; 6:3017-3021.
55. Weclawiak H, Ribes D, Guilbeau-Frugier C, et al. Relapse of membranous glomerulopathy after kidney transplantation: sustained remittance induced by rituximab. Clin Nephrol 2008; 69:373-376.
56. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10:89-98.
57. Andresdottir MB, Assmann KJ, Koene RA, Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoprolifera-tive glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998; 32:582-588.
58. West CD, Bissler JJ. Nephritic factor and recurrence in the renal transplant of membranoproliferative glomerulonephritis type II. Pediatr Nephrol 2008; 23:1867-1876.
59. Lorenz EC, Sethi S, Leung N, et al. Recurrent membranoproliferative glomer-ulonephritis after kidney transplantation. Kidney Int 2010; 77:721-728.
60. Braun MC, Stablein DM, Hamiwka LA, et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16:2225-2233.
61. Little MA, Dupont P, Campbell E, et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and posttransplantation recurrence risk. Kidney Int 2006; 69:504-511.
62. Wenderfer SE, Swinford RD, Mauiyyedi S, et al. Cytomegalovirus and recurrent idiopathic membranoproliferative glomerulonephritis type 1: cause or consequence? Transplantation 2007; 83:523-524.
63. Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apher 2002; 17:135-137.
64. Kamar N, Izopet J, Alric L, et al. Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008; 69:149-160.
65. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38:919-934.
66. Zeman M, Campbell P, Bain VG. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol 2006; 20:427-431.
67. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38:2308-2310.
68. Nachman PH, Segelmark M, Westman K, et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 1999; 56:1544-1550.
69. Gera M, Griffin MD, Specks U, et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupres-sion. Kidney Int 2007; 71:1296-1301.
70. NybergG, AkessonP, NordenG,Wieslander J. Systemic vasculitis in a kidney transplant population. Transplantation 1997; 63:1273-1277.
71. Sun Q, Cheng D, Wen J, et al. Successful renal transplantation in a patient with antineutrophil cytoplasmic autoantibody-associated microscopic poly-angiitis: effect of early plasma exchange and mycophenolate mofetil. Transplant Proc 2008; 40:3764-3766.
72. Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2:968-975.
73. Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V\+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19:2001-2010.
74. Stone JH, Millward CL, Olson JL, et al. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum 1998; 41:678-686.
75. Goral S, Ynares C, Shappell SB, et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003; 75:651-656.
76. Moroni G, Tantardini F, Gallelli B, et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005; 45:903-911.
77. Burgos PI, Perkins EL, Pons-Estel GJ, et al. Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. Arthritis Rheum 2009; 60:2757-2766.
78. Signori Baracat AL, Ribeiro-Alves MA, Alves-Filho G, Mazzali M. Systemic lupus erythematosus after renal transplantation: is complement a good marker for graft survival? Transplant Proc 2008; 40:746-748.
79. Thomas M, Blennerhassett J, Walker R. Relapse with transformation of lupus nephritis in a transplant kidney. Lupus 2005; 14:554-556.
80. Ponticelli C, Moroni G. Renal transplantation in lupus nephritis. Lupus 2005; 14:95-98.
81. Ghafari A, Etemadi J, Ardalan MR. Renal transplantation in patients with lupus nephritis: a single-center experience. Transplant Proc 2008; 40:143-144.
82. Sauter M, Schmid H, Anders HJ, et al. Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy. Clin Transplant 2009; 23:132-136.
83. Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant 2006; 10:651-657.
84. Leung N, Griffin MD, Dispenzieri A, et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005; 5:1660-1670.
85. Pronovost PH, Brady HR, Gunning ME, et al. Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immuno-tactoid glomerulopathy. Nephrol Dial Transplant 1996; 11:837-842.
86. Brady HR. Fibrillary glomerulopathy. Kidney Int 1998; 53:1421-1429.
87. Carles X, Rostaing L, Modesto A, et al. Successful treatment of recurrence of immunotactoid glomerulopathy in a kidney allograft recipient. Nephrol Dial Transplant 2000; 15:897-900.
88. Sathyan S, Khan FN, Ranga KV. A case of recurrent immunotactoid glomer-ulopathy in an allograft treated with rituximab. Transplant Proc 2009; 41:3953-3955.